Fredun Pharma Q2 FY27: PAT nearly doubles YoY (+97%), outpacing 86% revenue growth
PAT +96.93% YoY · revenue +86.41% · margins expanding
₹267.64 Cr
+86.41% YoY
₹18.57 Cr
+96.93% YoY
6.94%
+0.5pp YoY
₹10.99
Fredun Pharmaceuticals' consolidated numbers are the primary read here: PAT of ₹18.57 Cr grew 96.9% YoY (vs ₹9.43 Cr) and 41.4% QoQ (vs ₹13.13 Cr), outrunning revenue growth of 86.4% YoY and 17.5% QoQ to ₹267.64 Cr. Because profit grew faster than the top line, this is a genuine margin-led strong quarter rather than a volume story — net profit margin expanded to 6.94% from 6.49% a year ago and 5.75% last quarter, and neither period carries an exceptional item (both show ₹0.00 on that line), so the growth is clean, not one-off-driven.
Q2 FY-2027 vs prior quarters
The margin bridge sits mainly below the operating line: EBIT (PBT + finance cost) margin works out to roughly 14.4% of revenue this quarter, which already sits at or above the 12-13% EBIT margin management told its Q1 FY27 concall (17 Aug 2026) it expected to reach only "within 8-12 quarters" — i.e., the company looks ahead of its own margin-expansion timeline just one quarter in. Finance costs (₹8.78 Cr) and depreciation (₹3.93 Cr) both rose on the back of a larger asset base (gross block up from ₹11,760 Cr-equivalent to ₹15,184 Lakh-equivalent between March and September 2026), consistent with the ₹35-45 Cr/year capex plan flagged at the same concall.
The stock went into the print at ₹1,574.6, up 11.7% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
FY27 revenue target ~₹800 Cr (vs prior ₹570-580 Cr); 30-35% blended growth next 3 years; new-age businesses 35-45%, vintage 15-20%. CapEx ₹35-45 Cr/year next 2 years. Margin spike expected within 8-12 quarters to 12-13% EBIT.
— This quarter: beat
No street estimates or brokerage previews for this specific quarter turned up in search — Fredun is a sub-₹2,000 Cr micro-cap with no visible formal analyst coverage, so vsStreet is unknown rather than inferred. Against management's own guidance it reads as a beat-in-progress: H1 FY27 consolidated revenue of ~₹495.9 Cr is already 62% of the ~₹800 Cr FY27 revenue target management set out at the Q1 concall (versus a prior ₹570-580 Cr plan), putting the company well on pace barring an unusual H2 slowdown. Standalone PAT (₹18.83 Cr) is marginally ahead of consolidated (₹18.57 Cr) — the ₹0.26 Cr gap is drag from the three newly consolidated entities tied to the October 2026 pet-care and wellness expansion (two deals announced 8 Oct 2026), the first quarter these show up in group numbers.
W1
Whether quarterly revenue holds near ₹260-270 Cr in H2 FY27 to keep pace with management's ~₹800 Cr FY27 target (H1 already at ~₹496 Cr).
W2
Whether the three new pet-care/wellness subsidiaries (Fredun Retail, One Pet Stop, Wagr Retail) turn PAT-accretive or keep consolidated PAT trailing standalone PAT (currently ₹0.26 Cr behind).
W3
Progress on the board-approved NSE listing application and further share-count dilution from any remaining warrant conversions, given EPS growth is lagging PAT growth.
Statement bundles 'Other Operating Income' into 'Total income from operations' with no separate non-operating Other Income line, so otherIncome is null and totalIncome=revenueFromOperations; no exceptional items in any period shown; consolidated adds three new subsidiaries (Fredun Retail, One Pet Stop, Wagr Retail) from the Oct 2026 pet-care/wellness push; EPS for all comparative periods retrospectively bonus-adjusted (2:1 bonus allotted 16.07.2026) per note 7/8, not annualised.